Oral proteins and peptides market to hit $24b by 2030

Its expansion is attributed to the prevalence of chronic diseases like diabetes.

The global oral proteins and peptides market is projected to reach $24b by 2030 at a compound annual growth rate of 22%, according to MarketsandMarkets.

The sector’s expansion is attributed to the increasing prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases.

“Semaglutide, a GLP-1 receptor agonist, has captured a significant share of the market, primarily due to the increasing rates of diabetes, obesity, and overweight individuals,” the report said.

Moreover, developments in drug delivery technologies and patient preference for oral medication administration contribute to the market’s growth.